U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H28F2O4
Molecular Weight 394.4521
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIFLUCORTOLONE

SMILES

C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO

InChI

InChIKey=OGPWIDANBSLJPC-RFPWEZLHSA-N
InChI=1S/C22H28F2O4/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-21(15,3)22(14,24)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1

HIDE SMILES / InChI

Description

Diflucortolone (used in the form of valerate prodrug) is a corticosteroid developed for the treatment of inflammatory skin diseases. It is supposed that Diflucortolone acts by inducing Annexin A1, a phospholipase A2 inhibitory protein, and thus controls the biosynthesis of prostagladins and leukotrienes. The drug is marketed as a cream under the tradename Nerisone.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NERISONE
PubMed

PubMed

TitleDatePubMed
[Use of diflucortolone in various dermatological processes].
1976 Oct
[Clinical comparative study of between difluocortolone and flumethasone].
1977
[Clinical trial of diflucortolone. Preliminary report].
1981
A test of the half-side comparative design in the clinical evaluation of topical steroids, using diflucortolone and betamethasone creams.
1985 Oct
Local anti-inflammatory activity and systemic side effects of NM-135, a new prodrug glucocorticoid, in an experimental inflammatory rat model.
1998 Dec
Congenital infantile digital fibromatosis: a case report and review of the literature.
2009 Dec 28
Enhanced dermal delivery of diflucortolone valerate using lecithin/chitosan nanoparticles: in-vitro and in-vivo evaluations.
2013
Cutaneous polyarteritis nodosa successfully treated with topical diflucortolone valerate: a case report & review of the literature.
2014
Patents

Sample Use Guides

In Vivo Use Guide
Apply a thin layer and gently rub in using only enough to cover the affected area once or twice a day for a maximum of 4 weeks.
Route of Administration: Topical
In Vitro Use Guide
In the vasoconstriction test on human skin, in which hyperemia has been experimentally induced, a water/oil emulsion with 0.001% diflucortolone valerate is as effective as a similar preparation containing 0.1% fluocortolone.
Name Type Language
DIFLUCORTOLONE
INN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
DIFLUCORTOLONE [WHO-DD]
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 6,9-DIFLUORO-11,21-DIHYDROXY-16-METHYL-, (6.ALPHA.,11.BETA.,16.ALPHA.)-
Systematic Name English
DIFLUCORTOLONE [USAN]
Common Name English
DIFLUCORTOLONE [MART.]
Common Name English
6.ALPHA.,9-DIFLUORO-11.BETA.,21-DIHYDROXY-16.ALPHA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE
Systematic Name English
DIFLUCORTOLONE [INN]
Common Name English
DIFLUCORTOLONE [MI]
Common Name English
Classification Tree Code System Code
WHO-VATC QD07XC04
Created by admin on Tue Mar 06 11:58:17 UTC 2018 , Edited by admin on Tue Mar 06 11:58:17 UTC 2018
WHO-ATC D07AC06
Created by admin on Tue Mar 06 11:58:17 UTC 2018 , Edited by admin on Tue Mar 06 11:58:17 UTC 2018
WHO-ATC D07BC04
Created by admin on Tue Mar 06 11:58:17 UTC 2018 , Edited by admin on Tue Mar 06 11:58:17 UTC 2018
WHO-VATC QD07AC06
Created by admin on Tue Mar 06 11:58:17 UTC 2018 , Edited by admin on Tue Mar 06 11:58:17 UTC 2018
WHO-ATC D07XC04
Created by admin on Tue Mar 06 11:58:17 UTC 2018 , Edited by admin on Tue Mar 06 11:58:17 UTC 2018
WHO-VATC QD07BC04
Created by admin on Tue Mar 06 11:58:17 UTC 2018 , Edited by admin on Tue Mar 06 11:58:17 UTC 2018
Code System Code Type Description
EVMPD
SUB07128MIG
Created by admin on Tue Mar 06 11:58:17 UTC 2018 , Edited by admin on Tue Mar 06 11:58:17 UTC 2018
PRIMARY
MESH
D004060
Created by admin on Tue Mar 06 11:58:17 UTC 2018 , Edited by admin on Tue Mar 06 11:58:17 UTC 2018
PRIMARY
MERCK INDEX
M4432
Created by admin on Tue Mar 06 11:58:17 UTC 2018 , Edited by admin on Tue Mar 06 11:58:17 UTC 2018
PRIMARY Merck Index
ChEMBL
CHEMBL509924
Created by admin on Tue Mar 06 11:58:17 UTC 2018 , Edited by admin on Tue Mar 06 11:58:17 UTC 2018
PRIMARY
PUBCHEM
11954369
Created by admin on Tue Mar 06 11:58:17 UTC 2018 , Edited by admin on Tue Mar 06 11:58:17 UTC 2018
PRIMARY SWITZERF
ECHA (EC/EINECS)
220-022-6
Created by admin on Tue Mar 06 11:58:17 UTC 2018 , Edited by admin on Tue Mar 06 11:58:17 UTC 2018
PRIMARY
INN
2395
Created by admin on Tue Mar 06 11:58:17 UTC 2018 , Edited by admin on Tue Mar 06 11:58:17 UTC 2018
PRIMARY
NCI_THESAURUS
C87231
Created by admin on Tue Mar 06 11:58:17 UTC 2018 , Edited by admin on Tue Mar 06 11:58:17 UTC 2018
PRIMARY
DRUG BANK
DB09095
Created by admin on Tue Mar 06 11:58:17 UTC 2018 , Edited by admin on Tue Mar 06 11:58:17 UTC 2018
PRIMARY
RXCUI
3392
Created by admin on Tue Mar 06 11:58:17 UTC 2018 , Edited by admin on Tue Mar 06 11:58:17 UTC 2018
PRIMARY RxNorm
CAS
2607-06-9
Created by admin on Tue Mar 06 11:58:17 UTC 2018 , Edited by admin on Tue Mar 06 11:58:17 UTC 2018
PRIMARY
EPA CompTox
2607-06-9
Created by admin on Tue Mar 06 11:58:17 UTC 2018 , Edited by admin on Tue Mar 06 11:58:17 UTC 2018
PRIMARY